Beijing Hotgen Biotech Co.,Ltd. (688068.SH) has announced that its equity-invested company, Shenzhen Zhiyuan Biopharmaceutical Co., Ltd., reported through its wholly-owned subsidiary Beijing Zhiyuan Hongsheng Biopharmaceutical Co., Ltd. that the first patient with Alzheimer's disease has been enrolled and dosed in the Phase Ib clinical study of the innovative drug AA001 monoclonal antibody. The trial, titled "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of AA001 Monoclonal Antibody in Chinese Patients with Alzheimer's Disease-Related Mild Cognitive Impairment and Mild Alzheimer's Disease," is led by Professor Tang Yi and Professor Wei Cuibai from Xuanwu Hospital of Capital Medical University. A total of seven clinical centers across China are participating in the study. The trial protocol has received approval from the Ethics Committee of Xuanwu Hospital and recently achieved the milestone of enrolling and administering the dose to the first participant.